Harmony Biosciences Holdings (HRMY) Non-Current Debt (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Non-Current Debt data on file, last reported at $138.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt fell 12.24% year-over-year to $138.8 million; the trailing twelve-month figure through Mar 2026 stood at $138.8 million (down 12.24% YoY), and the FY2025 full-year result was $143.7 million, down 11.87% from the prior year.
• Non-Current Debt retreated to $138.8 million in Q1 2026, from $143.7 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $189.9 million in Q1 2022 to a low of $138.8 million in Q1 2026.
• A 5-year average of $170.9 million and a median of $175.0 million in 2024 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt retreated 0.18% in 2022 and declined 12.24% in 2026, its largest moves.
• Tracing HRMY's Non-Current Debt over 5 years: stood at $189.6 million in 2022, then retreated by 5.84% to $178.6 million in 2023, then decreased by 8.71% to $163.0 million in 2024, then retreated by 11.87% to $143.7 million in 2025, then decreased by 3.38% to $138.8 million in 2026.
• Business Quant data shows HRMY's Non-Current Debt at $138.8 million in Q1 2026, $143.7 million in Q4 2025, and $148.5 million in Q3 2025.